Search results
Showing 7471 to 7485 of 7707 results
Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]
Discontinued [GID-TA11209]
In development [GID-TA11165] Expected publication date: TBC
In development [GID-TA11472] Expected publication date: TBC
This guidance has been updated and replaced by NICE interventional procedures guidance 795.
EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence (MIB44)
This advice has been updated and replaced by NICE diagnostics guidance 34.
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)
This guidance has been updated and replaced by NICE technology appraisal guidance 1021.
Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (TA289)
This guidance has been updated and replaced by NICE technology appraisal guidance 386.
This appraisal has been updated and replaced by NICE technology appraisal guidance 195.
This guidance has been replaced by NICE guideline NG17.
Farco-fill Protect for indwelling urinary catheterisation (MIB121)
July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.
Lead with confidence through our Executive MSc in Healthcare Decision-Making.
More people are benefitting from NICE-recommended statins to reduce heart attacks and strokes
Around 5.3 million people in England were given a NICE-recommended statin or ezetimibe by their GP to help reduce their cholesterol during 2023/24, the largest number on record and almost 900,000 more than in 2022/23.
Introducing CHEERS-AI: improving health economic evaluation reporting for AI technologies
Our contribution to world-leading research.
Your voice is needed – my experience as a NICE committee member
Dr Raja discusses the vital role frontline NHS colleagues have on our independent committees, and how you can get involved.
Hundreds of people with multiple myeloma could receive a new, targeted treatment recommended for use within the Cancer Drugs Fund today (Tuesday, 29 October).